Invex Therapeutics Ltd News

Australia's Tax Agency Publishes Ruling on Invex Therapeutics' Capital Return

Invex Therapeutics Ltd (ASX:IXC) said in an Australian bourse filing on Wednesday that the Australian Taxation Office has published a class ruling relating to the company's AU$0.14 per share return of

MT NewswiresMar 19 23:07 ET

Invex Therapeutics Narrows Fiscal H1 Loss on Lower R&D Expenses

Invex Therapeutics (ASX:IXC) narrowed loss after tax attributable to members for the six months ended Dec. 31, 2023, to AU$2.1 million, or AU$0.0281 per share, from AU$3.8 million, or AU$0.0512 per sh

MT NewswiresFeb 15 20:51 ET

Invex Therapeutics, Peptron End Collaboration, Manufacturing Deal

Biopharmaceutical company Invex Therapeutics (ASX:IXC) and Peptron (KOSDAQ:087010) mutually terminated their collaboration and manufacturing agreement, according to a Friday release. Under the termina

MT NewswiresDec 21, 2023 22:53 ET

AU Morning Wrap: ASX Opens Lower; Bid Targets Adbri, Link Group Soar 30%

Stocks to watch: Adbri, Link Group, Stockland.

Moomoo News AUDec 17, 2023 18:54 ET

Invex Therapeutics to Secure European Patent Grant for Neurological Medication

Invex Therapeutics (ASX:IXC) received notice from the European Patent Office of its decision to grant a patent to the biopharmaceutical firm's Presendin medication for the treatment of certain neurolo

MT NewswiresNov 21, 2023 21:33 ET

Invex Therapeutics (ASX:IXC) Reports Setbacks in Enrollment For IIH EVOLVE Phase III Trial

The Market HeraldJun 28, 2023 01:31 ET

Invex Therapeutics (ASX:IXC) Receives European Orphan Drug Designation

The Market HeraldJun 23, 2023 01:50 ET

Invex Therapeautics (ASX:IXC) Lands Approval for Phase Three Clinical Trial in Germany

The Market HeraldMar 19, 2023 20:02 ET

Invex Therapeutics (ASX:IXC) Activates First US Clinical Site in IIH EVOLVE Phase III

The Market HeraldJan 19, 2023 00:21 ET

Invex Therapeutics (ASX:IXC) Gains Approval for Paediatric Plan From EMA

The Market HeraldDec 13, 2022 20:02 ET